What is Leerink Partnrs’ Forecast for VIR Q1 Earnings?

Vir Biotechnology, Inc. (NASDAQ:VIR) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Vir Biotechnology in a note issued to investors on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings of ($1.09) per share for the quarter. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s FY2025 earnings at ($3.80) EPS, FY2026 earnings at ($3.05) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($0.60) EPS.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. During the same quarter in the previous year, the firm posted ($1.22) EPS. The business’s revenue was down 9.8% compared to the same quarter last year.

A number of other research firms have also recently commented on VIR. JPMorgan Chase & Co. boosted their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a report on Friday, January 10th. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. Barclays cut their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Finally, Leerink Partners raised their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Vir Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.83.

Vir Biotechnology Price Performance

Shares of VIR opened at $10.05 on Wednesday. Vir Biotechnology has a 12 month low of $6.56 and a 12 month high of $14.45. The stock has a market cap of $1.38 billion, a PE ratio of -2.56 and a beta of 0.51. The stock’s 50-day moving average is $8.28 and its two-hundred day moving average is $8.39.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC raised its stake in Vir Biotechnology by 1.3% during the 3rd quarter. Barclays PLC now owns 550,186 shares of the company’s stock valued at $4,121,000 after acquiring an additional 7,287 shares in the last quarter. State Street Corp raised its stake in shares of Vir Biotechnology by 10.4% during the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after purchasing an additional 530,645 shares in the last quarter. Quarry LP raised its stake in shares of Vir Biotechnology by 901.8% during the third quarter. Quarry LP now owns 17,000 shares of the company’s stock valued at $127,000 after purchasing an additional 15,303 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Vir Biotechnology by 10.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 350,265 shares of the company’s stock worth $2,623,000 after purchasing an additional 33,473 shares during the period. Finally, Erste Asset Management GmbH bought a new position in Vir Biotechnology in the 3rd quarter valued at about $217,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the sale, the director now owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 14,786 shares of company stock valued at $170,172 over the last three months. Company insiders own 15.60% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).